Language: Spanish
References: 6
Page: 563-565
PDF size: 198.43 Kb.

Text Extraction

No abstract.

REFERENCES

1. Hernández-Marín I, Villavicencio-Delgado A, Velázquez- Piña L. Evaluación del efecto de la prasterona en el tratamiento del deseo sexual hipoactivo en mujeres posmenopáusicas. Ginecol Obstet Mex. 2019 mayo;87(5):288-294. htt ps://doi.org/10. 24245/gom. v87i5.2601.

2. Reglamento de la Ley General de Salud en Materia de Investigación para la Salud. https://www.gob.mx/cms/ uploads/attachment/file/281701/Reg_LGS_MIS.pdf) revisado 9/05/16.

3. Rosen, C. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. http://dx.doi.org/ 10.1080/009262300278597.

4. Scheffers, C., et al. Dehydroepiandrosterone for women in the peri or posmenopausal phase. Cochrane Database of Systematic Reviews. http://dx.doi.org/10.1002/14651858. CD011066.)

5. Weinberger JM, Houman J, Caron AT, Patel DN, Baskin AS, Ackerman AL, Eilber KS, Anger JT. Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis. Obstet Gynecol. 2018 Aug;132(2):453-458. doi: 10.1097/ AOG.0000000000002733.

6. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489. https://doi. org/10.1210/jc.2014-2260